Robert H. Smith School of Business
The Motley Fool

Market Foolery Featured Podcasts

  • MarketFoolery: 09.18.2014
    As Alibaba gears up for the biggest IPO in history, Motley Fool Funds analyst Tim Hanson shares why he has no interest in the stock.  Plus we analyze the business of the NFL, one company’s disappearing CEO, and things to do when you’re visiting Washington, DC.  
  • MarketFoolery: 09.17.2014
    Morgan Housel analyzes the best way to think about trends, what Scotland’s independence means for investors and what to do in DC.
  • MarketFoolery: 09.16.2014
    On today’s show the guys try to figure out what the future may hold for sears, what Microsoft plans to do with Minecraft, and which fall beer is the best.
Capital Business
Posted at 03:42 PM ET, 05/01/2012

Rockville-based Supernus Pharmaceuticals collects $50M in IPO

Rockville-based Supernus Pharmaceuticals raised $50 million in its initial public offering on Tuesday after selling 10 million shares of the biotechnology company at $5 a piece.

Supernus develops drugs to treat central nervous system disorders, including epilepsy, attention-deficit hyperactivity disorder and depression.

The company’s shares, listed on Nasdaq under the ticker SUPN, saw a lift in their first day on the market. As of 3 p.m., the stock price had climbed 15.5 percent to $5.77.

The initial price per share marked a sharp reduction compared to the price mentioned in previous regulatory filings. Until late last month, the company had said it would sell 5.8 million shares and hoped to fetch as much as $12 or $14 a piece.

The firm declared its plans to go public in December 2010 in a Securities and Exchange Commission filing.

IPOs have not been a common exit for the region’s biotechnology community in recent years. Instead, several companies have been acquired at heft prices. .

Rockville-based Micromet was scooped up for $1.16 billion in January by Thousand Oaks, Calif.-based Amgen. In December 2010, Columbia-based Martek Biosciences sold to Netherlands-based vitamin maker Royal DSM for $1.1. billion.

By  |  03:42 PM ET, 05/01/2012

 
Read what others are saying
     

    © 2011 The Washington Post Company